Dabigatran used beyond the initial 3 months of treatment at a dose of 150 mg twice daily reduced the risk of recurrent venous thromboembolism (VTE), according to a study published February 21 in the New England Journal of Medicine.
Dabigatran used beyond the initial 3 months of treatment at a dose of 150 mg twice daily reduced the risk of recurrent venous thromboembolism (VTE), according to a study published February 21 in the New England Journal of Medicine.
VTE is the third most common cardiovascular disorder after heart disease and stroke, and consists of 2 related conditions caused by blood clots: deep vein thrombosis and pulmonary embolism. There are an estimated 900,000 VTE events per year in the United States. Further, roughly one-third of people with VTE will have a recurrence within 10 years.
In 2 double-blind, randomized trials, RE-MEDY and RE-SONATE, the researchers compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with VTE who had completed at least 3 initial months of therapy.
In RE-MEDY, 2,856 patients were randomly assigned to dabigatran 150 mg (n=1,430) or warfarin (n=1,426) for an extended treatment period of 6 to 36 months. RE-MEDY demonstrated that treatment with dabigatran 150 mg twice daily was non-inferior to warfarin (P=0.01) in preventing recurrent VTE, including VTE-related death. There were fewer major bleeding events in patients with a prior history of VTE receiving dabigatran compared with those receiving warfarin. There was also a significantly lower risk (46%) of major or clinically relevant bleeding events in this same set of patients.
The RE-SONATE trial included 1,343 VTE patients, randomly assigned to dabigatran 150 mg (n=681) or placebo (n=662) for 6 months with extended follow-up to evaluate the long-term risk of recurrence (12 months after completion of study treatment). RE-SONATE demonstrated dabigatran was superior to placebo for the prevention of first recurrent or fatal VTE with a risk reduction of 92% during the treatment period (P<.001). Lower event rates were reported across all secondary efficacy end points for dabigatran over placebo.
The incidence of major bleeding was two patients in the dabigatran group versus none in the placebo group. Combined rates of major or clinically relevant bleeding were significantly higher in patients receiving dabigatran (n=36) as compared with those receiving placebo (n=12).
“Patients who suffer 1 VTE event are at increased risk of suffering another, with the risk accumulating over time, so it is important to investigate treatment that might help reduce the risk over an extended period of time,” said Sam Schulman, MD, PhD, FRCPC(C), lead study author and professor, department of medicine, McMaster University, Ontario, Canada.
“Most patients with VTE receive treatment for at least 3 months, longer for patients with risk factors for recurrence,” Dr Schulman told Formulary. “These trials assessed duration of treatment beyond 3 to 6 months, showing that dabigatran 150 mg twice daily reduces the risk of recurrent VTE. The results also indicate lower risk of clinically relevant bleeding with dabigatran compared to warfarin and a higher risk compared to placebo.”
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.